Viorel Jinga

Cardiovascular Complications Associated with Uro-Oncology Treatments—A Primer for the Clinician

Cardiovascular complications increasingly challenge survivors of urological cancers, given the cardiotoxicity of therapies such as androgen deprivation, vascular endothelial growth factor receptor inhibitors, tyrosine kinase inhibitors, immune checkpoint inhibitors, and chemother...